DRUG INTERVENTION RESPONSE PREDICTIONS WITH PARADIGM (DIRPP) IDENTIFIES DRUG RESISTANT CANCER CELL LINES AND PATHWAY MECHANISMS OF RESISTANCE

被引:0
作者
Brubaker, Douglas [1 ,2 ]
Difeo, Analisa [2 ]
Chen, Yanwen [2 ]
Pearl, Taylor [4 ]
Zhai, Kaide [2 ]
Bebek, Gurkan [1 ,2 ,3 ]
Chance, Mark [1 ,2 ]
Barnholtz-Sloan, Jill [1 ,2 ]
机构
[1] Case Western Reserve Univ, Sch Med, Case Ctr Prote & Bioinformat, BRB 932,10900 Euclid Ave, Cleveland, OH 44106 USA
[2] Case Western Reserve Univ, Sch Med, Case Comprehens Canc Ctr, Cleveland, OH 44106 USA
[3] Cleveland Clin, Lerner Res Inst, Genom Med Inst, Cleveland, OH 44195 USA
[4] MIT, Cambridge, MA 02139 USA
来源
PACIFIC SYMPOSIUM ON BIOCOMPUTING 2014 | 2014年
关键词
EXPRESSION;
D O I
暂无
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
The revolution in sequencing techniques in the past decade has provided an extensive picture of the molecular mechanisms behind complex diseases such as cancer. The Cancer Cell Line Encyclopedia (CCLE) and The Cancer Genome Project (CGP) have provided an unprecedented opportunity to examine copy number, gene expression, and mutational information for over 1000 cell lines of multiple tumor types alongside IC50 values for over 150 different drugs and drug related compounds. We present a novel pipeline called DIRPP, Drug Intervention Response Predictions with PARADIGM7, which predicts a cell line's response to a drug intervention from molecular data. PARADIGM (Pathway Recognition Algorithm using Data Integration on Genomic Models) is a probabilistic graphical model used to infer patient specific genetic activity by integrating copy number and gene expression data into a factor graph model of a cellular network. We evaluated the performance of DIRPP on endometrial, ovarian, and breast cancer related cell lines from the CCLE and CGP for nine drugs. The pipeline is sensitive enough to predict the response of a cell line with accuracy and precision across datasets as high as 80 and 88% respectively. We then classify drugs by the specific pathway mechanisms governing drug response. This classification allows us to compare drugs by cellular response mechanisms rather than simply by their specific gene targets. This pipeline represents a novel approach for predicting clinical drug response and generating novel candidates for drug repurposing and repositioning.
引用
收藏
页码:125 / 135
页数:11
相关论文
共 48 条
  • [41] MGr1-Ag/37LRP induces cell adhesion-mediated drug resistance through FAK/PI3K and MAPK pathway in gastric cancer
    Sun, Li
    Liu, Lili
    Liu, Xiangqiang
    Wang, Yafang
    Li, Mengbin
    Yao, Liping
    Yang, Jianjun
    Ji, Genlin
    Guo, Changcun
    Pan, Yanglin
    Liang, Shuhui
    Wang, Biaoluo
    Ding, Jie
    Zhang, Hongwei
    Shi, Yongquan
    CANCER SCIENCE, 2014, 105 (06) : 651 - 659
  • [42] Knockdown of RhoGDI2 represses human gastric cancer cell proliferation, invasion and drug resistance via the Rac1/Pak1/LIMK1 pathway
    Zeng, Ying
    Ren, Mei
    Li, Yukun
    Liu, Yanli
    Chen, Cong
    Su, Jian
    Su, Bo
    Xia, Hong
    Liu, Fang
    Jiang, Hao
    Ling, Hui
    Zeng, Xi
    Su, Qi
    CANCER LETTERS, 2020, 492 : 136 - 146
  • [43] miR-200c enhances sensitivity of drug-resistant non-small cell lung cancer to gefitinib by suppression of PI3K/Akt signaling pathway and inhibites cell migration via targeting ZEB1
    Zhou, Guohua
    Zhang, Fangli
    Guo, Yu
    Huang, Jianfei
    Xie, Yaqiong
    Yue, Shuanglei
    Chen, Minghui
    Jiang, Hao
    Li, Mengjie
    BIOMEDICINE & PHARMACOTHERAPY, 2017, 85 : 113 - 119
  • [44] circRNA hsa_circ_0005909 Predicts Poor Prognosis and Promotes the Growth, Metastasis, and Drug Resistance of Non-Small-Cell Lung Cancer via the miRNA-338-3p/SOX4 Pathway
    Song, He-Mei
    Meng, Dan
    Wang, Jin-Ping
    Zhang, Xiao-Yan
    DISEASE MARKERS, 2021, 2021
  • [45] Docosahexaenoic Acid Reverses Epithelial-Mesenchymal Transition and Drug Resistance by Impairing the PI3K/AKT/Nrf2/GPX4 Signalling Pathway in Docetaxel-Resistant PC3 Prostate Cancer Cells
    Shao, Z. C.
    Zhu, B. H.
    Huang, A. F.
    Su, M. Q.
    An, L. J.
    Wu, Z. P.
    Jiang, Y. J.
    Guo, H.
    Han, X. -Q.
    Liu, C. -M.
    FOLIA BIOLOGICA, 2022, 68 (02) : 59 - 71
  • [46] A novel miR-365-3p/EHF/keratin 16 axis promotes oral squamous cell carcinoma metastasis, cancer stemness and drug resistance via enhancing 5-integrin/c-met signaling pathway
    Huang, Wei-Chieh
    Jang, Te-Hsuan
    Tung, Shiao-Lin
    Yen, Tzu-Chen
    Chan, Shih-Hsuan
    Wang, Lu-Hai
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2019, 38 (1)
  • [47] RETRACTED: The miR 495-UBE2C-ABCG2/ERCC1 axis reverses cisplatin resistance by downregulating drug resistance genes in cisplatin-resistant non-small cell lung cancer cells (Retracted article. See vol. 63, 2021)
    Guo, Jiwei
    Jin, Dan
    Wu, Yan
    Yang, Lijuan
    Du, Jing
    Gong, Kaikai
    Chen, Weiwei
    Dai, Juanjuan
    Miao, Shuang
    Xi, Sichuan
    EBIOMEDICINE, 2018, 35 : 204 - 221
  • [48] RETRACTED: Extracellular vesicle-encapsulated microRNA-425-derived from drug-resistant cells promotes non-small-cell lung cancer progression through DAPK1-medicated PI3K/AKT pathway (Retracted Article)
    Guo, Zhihua
    Ye, Huangyang
    Zheng, Xiaobin
    Yin, Weiqiang
    He, Jianxing
    JOURNAL OF CELLULAR PHYSIOLOGY, 2021, 236 (05) : 3808 - 3820